These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35219584)

  • 1. Mesenchymal stem/stromal cell-based therapies for COVID-19: First iteration of a living systematic review and meta-analysis: MSCs and COVID-19.
    Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Cytotherapy; 2022 Jun; 24(6):639-649. PubMed ID: 35219584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval.
    Kirkham AM; Bailey AJM; Monaghan M; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Stem Cells Transl Med; 2022 Jul; 11(7):675-687. PubMed ID: 35758400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
    Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?
    Kirkham AM; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Cytotherapy; 2023 Mar; 25(3):341-352. PubMed ID: 36333234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.
    Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F
    Front Immunol; 2023; 14():1200180. PubMed ID: 37415976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
    Lu W; Yan L; Tang X; Wang X; Du J; Zou Z; Li L; Ye J; Zhou L
    J Transl Med; 2024 Jun; 22(1):550. PubMed ID: 38851730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
    Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
    Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial.
    Zarrabi M; Shahrbaf MA; Nouri M; Shekari F; Hosseini SE; Hashemian SR; Aliannejad R; Jamaati H; Khavandgar N; Alemi H; Madani H; Nazari A; Amini A; Hassani SN; Abbasi F; Jarooghi N; Fallah N; Taghiyar L; Ganjibakhsh M; Hajizadeh-Saffar E; Vosough M; Baharvand H
    Stem Cell Res Ther; 2023 Jun; 14(1):169. PubMed ID: 37365605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.
    Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L
    Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials.
    Liu Q; Ma F; Zhong Y; Wang G; Hu L; Zhang Y; Xie J
    Stem Cell Res Ther; 2023 May; 14(1):118. PubMed ID: 37143167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
    Xu Z; Huang Y; Zhou J; Deng X; He W; Liu X; Li Y; Zhong N; Sang L
    Front Immunol; 2021; 12():738697. PubMed ID: 34659231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19.
    Xiong J; Chen L; Zhang L; Bao L; Shi Y
    Cell Transplant; 2021; 30():963689721995455. PubMed ID: 33650894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
    Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
    Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
    Al-Khawaga S; Abdelalim EM
    Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
    Chen L; Qu J; Kalyani FS; Zhang Q; Fan L; Fang Y; Li Y; Xiang C
    Cell Mol Life Sci; 2022 Feb; 79(3):142. PubMed ID: 35187617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of mesenchymal stem cells in the clinical treatment of COVID-19.
    Li L; Zhang X; Wu Y; Xing C; Du H
    Cell Tissue Res; 2024 Jun; 396(3):293-312. PubMed ID: 38512548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
    Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P
    Front Immunol; 2020; 11():1091. PubMed ID: 32574263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.